Renale Denervation bei nicht-kontrollierter arterieller Hypertonie
Standard
Renale Denervation bei nicht-kontrollierter arterieller Hypertonie. / Vonend, Oliver; Böhm, Michael; Eckert, Siegfried; Hausberg, Martin; Rittger, Harald; Rump, Lars-Christian; Schmieder, Roland; Schulte, Karl-Ludwig; Schunkert, Heribert; Uder, Michael; Veelken, Roland; Vorwerk, Dierk; Weil, Joachim; Wenzel, Ulrich; Mahfoud, Felix.
in: DEUT MED WOCHENSCHR, Jahrgang 140, Nr. 5, 03.2015, S. 363.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Renale Denervation bei nicht-kontrollierter arterieller Hypertonie
AU - Vonend, Oliver
AU - Böhm, Michael
AU - Eckert, Siegfried
AU - Hausberg, Martin
AU - Rittger, Harald
AU - Rump, Lars-Christian
AU - Schmieder, Roland
AU - Schulte, Karl-Ludwig
AU - Schunkert, Heribert
AU - Uder, Michael
AU - Veelken, Roland
AU - Vorwerk, Dierk
AU - Weil, Joachim
AU - Wenzel, Ulrich
AU - Mahfoud, Felix
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2015/3
Y1 - 2015/3
N2 - Arterial hypertension is a major risk factor for cardiovascular mortality and remains insufficiently controlled in Germany. The sham controlled Symplicity HTN-3 trial did meet its primary safety endpoint but failed to meet its primary efficacy endpoint. Renal denervation can not replace established, well-proven therapies. It can only be used in selected truly resistant hypertensive patients as an additive approach and should be performed by specialized centers only. Randomized controlled trials are needed to further evaluate renal denervation.
AB - Arterial hypertension is a major risk factor for cardiovascular mortality and remains insufficiently controlled in Germany. The sham controlled Symplicity HTN-3 trial did meet its primary safety endpoint but failed to meet its primary efficacy endpoint. Renal denervation can not replace established, well-proven therapies. It can only be used in selected truly resistant hypertensive patients as an additive approach and should be performed by specialized centers only. Randomized controlled trials are needed to further evaluate renal denervation.
KW - Antihypertensive Agents/therapeutic use
KW - Clinical Trials as Topic
KW - Combined Modality Therapy
KW - Cooperative Behavior
KW - Coronary Vasospasm/surgery
KW - Germany
KW - Humans
KW - Hypertension/surgery
KW - Interdisciplinary Communication
KW - Renal Artery/innervation
KW - Societies, Medical
KW - Sympathectomy/methods
U2 - 10.1055/s-0041-100835
DO - 10.1055/s-0041-100835
M3 - SCORING: Zeitschriftenaufsatz
C2 - 25734680
VL - 140
SP - 363
JO - DEUT MED WOCHENSCHR
JF - DEUT MED WOCHENSCHR
SN - 0012-0472
IS - 5
ER -